Startup profile · funding coverage
R1 Therapeutics funding, valuation and investors
Clinical-stage kidney-disease therapeutics company developing AP306
Keep track of R1 Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A extension
$3M incremental; $80.5M cumulative · September 30, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$81M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Redwood City, United States
Investors in latest funding
Other: Samsara BioCapital
Overview
R1 Therapeutics develops first-in-class therapies for kidney disease. Its lead program, AP306, is a pan phosphate active-transport inhibitor being tested as a monotherapy for hyperphosphatemia in dialysis patients.
Why R1 Therapeutics is interesting
R1's Series A grew from $77.5 million to $80.5 million shortly before expected Phase 2b data in the first half of 2027, but only $3 million of the September announcement was incremental.
Product & use cases
AP306 is an oral pan phosphate transporter inhibitor licensed outside Greater China from Alebund Pharmaceuticals and currently in a global Phase 2b study.
- Treatment of hyperphosphatemia in chronic kidney disease patients on dialysis
Key facts
- Series A expanded by $3M to $80.5M on September 30, 2026
- Phase 2b topline data expected in H1 2027
- Samsara BioCapital joined the existing investor syndicate
Funding history (newest first)
Series A extension
2026-09-30 $3M incremental; $80.5M cumulativeSeries A
2026-03 $77.5M- Abingworth (lead)
- DaVita Venture Group (lead)
- F-Prime Capital (lead)
- Curie.Bio (participant)
- SNMA Capital (participant)
- U.S. Renal Care (participant)
Source: https://www.r1therapeutics.com/
Investors in our directory
Funds linked from R1 Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: AP306 is designed to block three active phosphate transporters in the gut, offering a mechanism distinct from traditional phosphate binders.
R1 competes with established phosphate-binder therapies and other experimental approaches to hyperphosphatemia. Its financing case depends heavily on Phase 2b efficacy, safety and treatment-burden data.
-
Ardelyx direct
Markets Xphozah for phosphate absorption control in dialysis patients.
-
Phosphate binders incumbent
Long-standing standard of care with adherence and pill-burden limitations.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.